ESMO 2025 preview – Enhertu's early breast hat-trick
The ESMO presidential session will feature data from Destiny-Breast05 and 11.
ESMO 2025 preview – a bemarituzumab reckoning approaches
Meanwhile, Astra, Merck and Novartis look for new Enhertu, Keytruda and Pluvicto additions.
HengRui presses on in HER3, despite Merck’s failure
The Chinese group will soon start a pivotal trial of its ADC ruza-can in first-line NSCLC.
FDA doubles down on overall survival
New draft guidance could see the agency getting ever stricter.
FDA red and green lights: June 2025
Controversial nods came for Urogen’s Zusduri and Astra/Daiichi’s Datroway.
Better late than never for Datroway in lung cancer
Astra/Daiichi have trumped Gilead’s Trodelvy with a lung cancer approval.
NextCure joins Merck in an ovarian target
But the former is paying a fraction of what Merck shelled out for raludotatug.
ASCO 2025 – Enhertu mounts its first-line charge
Enhertu plus Perjeta shows a convincing progression-free survival benefit over a Perjeta triplet.
